Ambeed.cn

首页 / / / / WP1066

WP1066 98%

货号:A203794 Ambeed 开学季,买赠积分,赢豪礼

WP1066是一种 JAK2STAT3 抑制剂,也影响 STAT5ERK1/2,而不影响 JAK1JAK3

WP1066 化学结构 CAS号:857064-38-1
WP1066 化学结构
CAS号:857064-38-1
WP1066 3D分子结构
CAS号:857064-38-1
WP1066 化学结构 CAS号:857064-38-1
WP1066 3D分子结构 CAS号:857064-38-1
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

WP1066 纯度/质量文件 产品仅供科研

货号:A203794 标准纯度: 98%
批次查询: 批次纯度:

全球学术期刊中引用的产品

Cell,2024. Ambeed. [ A125712 ]
Cancer Discov., 2024. Ambeed. [ A285925 ]
JMC, 2024, 67(17): 14974-14985. Ambeed. [ A288696 ]
JMC, 2024, 67(17): 15061-15079. Ambeed. [ A524399 , A633512 , A144280 , A174613 ]
EJNMMI Radiopharm. Chem., 2024, 9, 61. Ambeed. [ A1257961 , A622068 ]
更多 >
产品名称 JAK1 JAK2 JAK3 Tyk2 其他靶点 纯度
Decernotinib +++

JAK1, IC50: 11 nM

JAK1, Ki: 11 nM

+++

JAK2, Ki: 13 nM

++++

JAK3, Ki: 2.5 nM

+++

TYK2, Ki: 13 nM

99%+
ZM39923 HCl +

JAK1, pIC50: 4.4

+

JAK3, pIC50: 7.1

EGFR 97%
Cerdulatinib +++

JAK1, IC50: 12 nM

+++

JAK2, IC50: 6 nM

+++

JAK3, IC50: 8 nM

++++

TYK2, IC50: 0.5 nM

99%+
Momelotinib +++

JAK1, IC50: 11 nM

++

JAK2, IC50: 18 nM

+

JAK3, IC50: 155 nM

99%+
XL019 +

JAK1, IC50: 134.3 nM

++++

JAK2, IC50: 2.2 nM

+

JAK3, IC50: 214.2 nM

FLT3 99%+
Ruxolitinib +++

JAK1, IC50: 3.3 nM

++++

JAK2, IC50: 2.8 nM

98%
Tofacitinib +

JAK1, IC50: 112 nM

++

JAK2, IC50: 20 nM

++++

JAK3, IC50: 1 nM

98%
Ruxolitinib (S enantiomer) +++

JAK1, IC50: 3.3 nM

++++

JAK2, IC50: 2.8 nM

++

TYK2, IC50: 19 nM

98%
Filgotinib +++

JAK1, IC50: 10 nM

++

JAK2, IC50: 28 nM

+

JAK3, IC50: 810 nM

+

TYK2, IC50: 116 nM

99%
Baricitinib +++

JAK1, IC50: 5.9 nM

+++

JAK2, IC50: 5.7 nM

++

TYK2, IC50: 53 nM

99%
Gandotinib ++

JAK1, IC50: 19.8 nM

++++

JAK2 (V617F), Ki: 0.245 nM

JAK2, IC50: 0.288 nM

++

JAK3, IC50: 48.0 nM

++

TYK2, IC50: 44 nM

FLT3 99%+
Oclacitinib maleate +++

JAK1, IC50: 10nM

++

JAK2, IC50: 18nM

+

JAK3, IC50: 99nM

+

TYK2, IC50: 84nM

98+%
NVP-BSK805 2HCl ++

JAK1, IC50: 31.63 nM

++++

JAK2, IC50: ~0.5 nM

++

JAK3, IC50: 18.68 nM

+++

TYK2, IC50: 10.76 nM

99+%
Peficitinib 98%
Go6976 FLT3 99%+
AZD-1480 ++++

JAK2, IC50: 0.26 nM

99%+
Fedratinib +++

JAK2 (V617F), IC50: 3 nM

JAK2, IC50: 3 nM

RET,FLT3 99%+
WP1066 +

JAK2, IC50: 2.3 μM

98%
Curcumol 98%
AZ960 ++++

JAK2, Ki: 0.45 nM

JAK2, IC50: <3 nM

97%
GLPG0634 analog 99%+
CEP-33779 ++++

JAK2, IC50: 1.8 nM

99%+
FLLL32 +

JAK2, IC50: <5 μM

99%+
WHI-P154 +

JAK3, IC50: 1.8 μM

EGFR,VEGFR,Src 98%
BMS-911543 ++++

JAK2, IC50: 1.1 nM

+

JAK3, IC50: 75 nM

++

TYK2, IC50: 66 nM

98%
TG101209 +++

JAK2, IC50: 6 nM

+

JAK3, IC50: 169 nM

RET,FLT3 99%+
AT9283 ++++

JAK2, IC50: 1.2 nM

++++

JAK3, IC50: 1.1 nM

99%+
Pacritinib ++

JAK2 (V617F), IC50: 19 nM

JAK2, IC50: 23 nM

+

JAK3, IC50: 520 nM

++

TYK2, IC50: 50 nM

FLT3 97%
Tofacitinib citrate ++

JAK2, IC50: 20 nM

++++

JAK3, IC50: 1 nM

99%
FM-381 ++++

JAK3, IC50: 127 pM

98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。
产品名称 STAT1 STAT3 STAT5 其他靶点 纯度
Nifuroxazide 98%
Fludarabine 98%
Artesunate 98%
BP-1-102 +++

STAT3, Kd: 504 nM

99%+
Niclosamide ++

STAT3, IC50: 0.7 μM

98%
Napabucasin 98%
Cryptotanshinone ++

STAT3, IC50: 4.6 μM

98%
Stattic +

STAT3, IC50: 5.1 μM

98%
NSC 74859 +

STAT3, IC50: 86 μM

99%+
Ochromycinone 98%
HO-3867 97%
C188-9 ++++

STAT3, Kd: 4.7 nM

99%+
HJC0152 98%
SH5-07 97%
SH-4-54 ++++

STAT3, Kd: 300 nM

+++

STAT5, Kd: 464 nM

99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。

WP1066 生物活性

靶点
  • JAK2

    JAK2, IC50:2.3 μM

描述 The JAK/STAT3 pathway is activated by various cancer types, including glioma, and blockade of the pathway induces cell death in cancer cells. Thus, the JAK/STAT3 pathway is a target for cancer therapy. WP1066 induces degradation of JAK2 and inhibition of its phosphorylation. WP1066 also degraded JAK2 protein, thereby blocking its downstream signal transducer and activator of transcription (STAT) and phosphoinositide-3-kinase pathways[3]. WP1066 is a most potent, small molecule, nonphosphorylated STAT3 inhibitor, that strongly binds to STAT3 protein with KD of 300 nM. The IC50 value in HEL cells is 2.3 μM[4]. In a vitro study, AML (acute myelocytic leukemia) cells obtained from the four patients with AML were cultured using the AML blast colony culture assay with or without WP1066 at concentrations ranging from 0.5 to 3.0 μM. The result showed that WP1066 inhibited the proliferation of AML blast colony-forming cells in a dose-dependent manner[5]. In a vivo study, mice with intracerebral melanoma were treated with WP1066 at a dose of 40 mg/kg for 21 days. The result showed that WP1066 could significantly increase the survival rate of intracerebral melanoma mice[6]. Use WP1066 at different concentrations from 0 to10 µM on SNK6 cells to demonstrate the influence of WP1066 on protein expression of p-STAT3 and downstream molecules. The decrease of protein expression for p-STAT3 in SNK6 cells after a 24-h treatment of WP1066 in a dose-dependent manner which indicated the inhibition of the pro-survival factors downstream of STAT3 pathway may be the potential mechanisms contributing to the antitumor effect of WP1066 in nasal NKTCL(Nasal-type natural killer/T-cell lymphoma) cells[7].
作用机制 WP1066 can strongly bind to STAT3 protein and bind to the enzyme pocket of JAK2.

WP1066 细胞研究

细胞系 浓度 检测类型 检测时间 活动说明 数据源
human 30M cells Cytotoxic assay 8 days Cytotoxicity against human 30M cells assessed as cell viability after 8 days by Alamar Blue assay, IC50=1.8 μM 24900612
human 73M cells Cytotoxic assay 8 days Cytotoxicity against human 73M cells assessed as cell viability after 8 days by Alamar Blue assay, IC50=2.1 μM 24900612
human MM1 cells Function assay 24-72 h Antitumor activity against human MM1 cells after 24 to 72 hrs by MTT assay, ic50=1.2 μM 22036213
human OCI-My4 cells Function assay 24-72 h Antitumor activity against human OCI-My4 cells after 24 to 72 hrs by MTT assay, IC50=1.8 μM 22036213

WP1066 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT01904123 Metastatic Malignant Neoplasm ... 展开 >>in the Brain Metastatic Melanoma Recurrent Brain Neoplasm Recurrent Glioblastoma Recurrent Malignant Glioma 收起 << Phase 1 Recruiting July 31, 2021 United States, Texas ... 展开 >> M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Amy B. Heimberger    713-563-8717       Principal Investigator: Amy B. Heimberger 收起 <<

WP1066 参考文献

[1]Tsurumaki H, Katano H, Sato K, Imai R, Niino S, Hirabayashi Y, Ichikawa S. WP1066, a small molecule inhibitor of the JAK/STAT3 pathway, inhibits ceramide glucosyltransferase activity. Biochem Biophys Res Commun. 2017 Sep 16;491(2):265-270. doi: 10.1016/j.bbrc.2017.07.115. Epub 2017 Jul 21. PMID: 28739255.

[2]Verstovsek S, Manshouri T, Quintás-Cardama A, Harris D, Cortes J, Giles FJ, Kantarjian H, Priebe W, Estrov Z. WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation. Clin Cancer Res. 2008 Feb 1;14(3):788-96. doi: 10.1158/1078-0432.CCR-07-0524. PMID: 18245540.

[3]Ferrajoli A, Faderl S, Van Q, Koch P, Harris D, Liu Z, Hazan-Halevy I, Wang Y, Kantarjian HM, Priebe W, Estrov Z. WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells. Cancer Res. 2007 Dec 1;67(23):11291-9. doi: 10.1158/0008-5472.CAN-07-0593. PMID: 18056455.

[4]Hatiboglu MA, Kong LY, Wei J, Wang Y, McEnery KA, Fuller GN, Qiao W, Davies MA, Priebe W, Heimberger AB. The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models. Int J Cancer. 2012 Jul 1;131(1):8-17. doi: 10.1002/ijc.26307. Epub 2011 Aug 24. PMID: 21792892; PMCID: PMC3319790.

[5]Geng L, Li X, Zhou X, Fang X, Yuan D, Wang X. WP1066 exhibits antitumor efficacy in nasal‑type natural killer/T-cell lymphoma cells through downregulation of the STAT3 signaling pathway. Oncol Rep. 2016 Nov;36(5):2868-2874. doi: 10.3892/or.2016.5091. Epub 2016 Sep 15. PMID: 27633398.

WP1066 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.81mL

0.56mL

0.28mL

14.04mL

2.81mL

1.40mL

28.07mL

5.61mL

2.81mL

WP1066 技术信息

CAS号857064-38-1
分子式C17H14BrN3O
分子量 356.217
别名
运输蓝冰
存储条件

粉末 Inert atmosphere,2-8°C

液体 -20°C:3-6个月-80°C:12个月

溶解度

DMSO: 45 mg/mL(126.33 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

无水乙醇: 15 mg/mL(42.11 mM),配合低频超声助溶,注意:无水乙醇开封后,易挥发,也会吸收空气中的水分,导致溶解能力下降,请避免使用开封较久的乙醇

动物实验配方

IP 2% DMSO+2% Tween80+40% PEG300+water 3.9 mg/mL clear

PO 0.5% CMC-Na 35 mg/mL suspension

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。